Rare disease is a major social issue and concerns every family in the long run. As a patient-driven biotech company, ReflectionBio® welcomes partners who share our value in helping the rare disease community by developing life-changing treatments. Since inception, ReflectionBio® has partnered with leading research institutes, contract research organizations (CROs), contract manufacturing organization (CMO0) and consultants to advance our R&D.
ReflectionBio® owns worldwide intellectual property rights in gene therapy for treating Bietti’s Crystalline Dystrophy (BCD). Our BCD gene therapy program has received Orphan Drug Designation from the U.S. FDA. Retinal specialists in Asia, Europe and North America have expressed interest in participating in BCD gene therapy clinical trials.
If you are interested in partnering with ReflectionBio®, please email us at email@example.com